Trial · NCT03355664
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm | 42 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | 42 day | The numbers analysed differ from the overall total as for this secondary analysis we report efficacy stratified by each of the 3 study sites. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Parasite Clearance Half-life | 42 day | Hours | MEAN | |
| SECONDARY | Fever Clearance Time | 42 day | Hours to fever clearance | MEAN | |
| SECONDARY | Number of Severe Adverse Events by Study Arm | 42 days | Participants | NUMBER | |
| SECONDARY | Incidence of Adverse Events Concerning Markers of Hepatic or Renal Toxicity | 42 day | Events | NUMBER | |
| SECONDARY | Incidence of Prolongation of the Corrected QT Interval | 28 day | Events | NUMBER | |
| SECONDARY | Prolongation of the Corrected QT Interval | Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points | Events | NUMBER | |
| SECONDARY | Parasite Reduction Rates | 24 and 48 hours | |||
| SECONDARY | Parasite Count to Fall 50% | 42 days | |||
| SECONDARY | Parasite Count to Fall 90% | 42 days | |||
| SECONDARY | Parasite Count to Fall 99% | 42 days | |||
| SECONDARY | Change in Haematocrit | Day 1 to 7, 14, 21, 28, 35, 42 | |||
| SECONDARY | Correlation Between the Host Genotype and the Pharmacokinetics and Pharmacodynamics of Antimalarials | 42 day | |||
| SECONDARY | Proportion of Patients That Reports Completing a Full Course of Observed TACT or ACT | 42 day | |||
| SECONDARY | Prevalence of Kelch13 Mutations of Known Significance | 42 day | |||
| SECONDARY | Prevalence/Incidence of Other Genetic Markers of Antimalarial Drug Resistance Such as Multidrug Resistance Gene 1 Copy Number and Multidrug Resistance Gene 1 Mutations | 48 hours | |||
| SECONDARY | Genome Wide Association With in Vivo/in Vitro Sensitivity Parasite Phenotype | 42 day | |||
| SECONDARY | Correlation Between Single Nucleotide Polymorphisms and Whole Genome Sequencing | 42 day | |||
| SECONDARY | A Comparison of Transcriptomic Patterns Between Sensitive and Resistant Parasites | baseline and t = 6 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03355664/outcomes